BeiGene Valuation

49BA Stock  EUR 294.00  2.00  0.68%   
At this time, the firm appears to be overvalued. BeiGene shows a prevailing Real Value of €244.47 per share. The current price of the firm is €294.0. Our model approximates the value of BeiGene from analyzing the firm fundamentals such as Return On Equity of 0.0181, profit margin of 0.01 %, and Current Valuation of 31.41 B as well as examining its technical indicators and probability of bankruptcy.
Price Book
9.3606
Enterprise Value
31.4 B
Enterprise Value Ebitda
109.4482
Price Sales
6.5424
Forward PE
43.4783
Overvalued
Today
294.00
Please note that BeiGene's price fluctuation is very steady at this time. Calculation of the real value of BeiGene is based on 3 months time horizon. Increasing BeiGene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BeiGene stock is determined by what a typical buyer is willing to pay for full or partial control of BeiGene. Since BeiGene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BeiGene Stock. However, BeiGene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  294.0 Real  244.47 Hype  294.16 Naive  299.75
The real value of BeiGene Stock, also known as its intrinsic value, is the underlying worth of BeiGene Company, which is reflected in its stock price. It is based on BeiGene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BeiGene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
242.16
Downside
244.47
Real Value
323.40
Upside
Estimating the potential upside or downside of BeiGene helps investors to forecast how BeiGene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BeiGene more accurately as focusing exclusively on BeiGene's fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-5.39-5-3.45
Details
Hype
Prediction
LowEstimatedHigh
291.85294.16296.47
Details
Naive
Forecast
LowNext ValueHigh
297.44299.75302.07
Details

BeiGene Cash

2.09 Billion

BeiGene Total Value Analysis

BeiGene is presently forecasted to have takeover price of 31.41 B with market capitalization of 32.53 B, debt of 851.53 M, and cash on hands of 1.54 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BeiGene fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
31.41 B
32.53 B
851.53 M
1.54 B

BeiGene Investor Information

About 17.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from BeiGene's historical financial statements, BeiGene is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.

BeiGene Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BeiGene has an asset utilization ratio of 64.35 percent. This implies that the Company is making €0.64 for each dollar of assets. An increasing asset utilization means that BeiGene is more efficient with each dollar of assets it utilizes for everyday operations.
 
Covid
 
Interest Hikes

BeiGene Profitability Analysis

Based on the measurements of profitability obtained from BeiGene's financial statements, BeiGene may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess BeiGene's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2019-06-30
Previous Quarter
94.3 M
Current Value
124.8 M
Quarterly Volatility
229.9 M
 
Covid
 
Interest Hikes
The BeiGene's current Gross Profit is estimated to increase to about 3.9 B
For BeiGene profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BeiGene to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BeiGene utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BeiGene's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BeiGene over time as well as its relative position and ranking within its peers.

BeiGene Earnings per Share Projection vs Actual

By analyzing BeiGene's earnings estimates, investors can diagnose different trends across BeiGene's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for BeiGene is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
BeiGene is projected to generate -5.0 in earnings per share on the 30th of September 2022. BeiGene earnings estimates show analyst consensus about projected BeiGene EPS (Earning Per Share). It derives the highest and the lowest estimates based on BeiGene's historical volatility. Many public companies, such as BeiGene, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

BeiGene Ownership Allocation

BeiGene holds a total of 101.81 Million outstanding shares. 30% of BeiGene outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

BeiGene Profitability Analysis

The company reported the revenue of 3.81 B. Net Loss for the year was (644.79 M) with profit before overhead, payroll, taxes, and interest of 4.29 B.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BeiGene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BeiGene and how it compares across the competition.

About BeiGene Valuation

The stock valuation mechanism determines BeiGene's current worth on a weekly basis. Our valuation model uses a comparative analysis of BeiGene. We calculate exposure to BeiGene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BeiGene's related companies.
Last ReportedProjected for Next Year
Gross Profit3.7 B3.9 B

Complementary Tools for BeiGene Stock analysis

When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Transaction History
View history of all your transactions and understand their impact on performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites